Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck. -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (347)	1/22/2000 11:41:00 AM
From: Mike McFarland	Respond to of 743

I guess this should be on a genomics thread, but what the heck, we wander all over SI with our chit chat: What I'd like to see, to value GLGC, Curagen and the likes--is the marketcap per SNP (where a Genset might look like a good value) or the maretcap compared to number of database subscriptions, where glgc or incy might look particularly strong, or the cap per base pair patented, hmmm. It is too complicated for the casual trader--which is part of the reason one becomes an investor in some of these (wish I'd been a better investor with glgc, shit!)--you buy and wait for the Street to discover your company's story, patience is key. Well, I suppose no patience is required to do the momentum thing, I must just have some sort of a mental block on that--I hate to chase anything (for instance, it will be increasingly frustrating to watch nbix cruise on up to $50, while I sit on my snap). Of course I cant beat myself up too much--I'd probably have sold glgc after a triple and not made all that much anyway--not one to let profits run as much as I should. I expect glgc is going to $100 now, a nice even number for the traders to shoot for.